1 |
GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways
|
|
|
|
BASE
|
|
Show details
|
|
3 |
Polymorphisms in the interleukin 4, interleukin 13 and corresponding receptor genes are not associated with systemic sclerosis and do not influence gene expression
|
|
|
|
BASE
|
|
Show details
|
|
4 |
Variants of PBEF predispose to systemic sclerosis and pulmonary arterial hypertension development
|
|
|
|
BASE
|
|
Show details
|
|
5 |
Identification of novel genetic markers associated with the clinical phenotypes of systemic sclerosis through a genome wide association strategy
|
|
|
|
BASE
|
|
Show details
|
|
6 |
Variants of PBEF predispose to systemic sclerosis and pulmonary arterial hypertension development
|
|
|
|
BASE
|
|
Show details
|
|
7 |
Polymorphisms in the interleukin 4, interleukin 13 and corresponding receptor genes are not associated with Systemic Sclerosis and do not influence gene expression
|
|
|
|
BASE
|
|
Show details
|
|
8 |
A large multicentre analysis of CTGF -945 promoter polymorphism does not confirm association with systemic sclerosis susceptibility or phenotype
|
|
|
|
BASE
|
|
Show details
|
|
9 |
The interleukin 23 receptor gene does not confer risk to systemic sclerosis and is not associated with systemic sclerosis disease phenotype
|
|
|
|
BASE
|
|
Show details
|
|
10 |
The Interleukin 23 Receptor gene does not confer risk to systemic sclerosis and is not associated with SSc disease phenotype
|
|
|
|
BASE
|
|
Show details
|
|
11 |
A large multicenter analysis of CTGF -945 promoter polymorphism does not confirm association with Systemic Sclerosis susceptibility or phenotype
|
|
|
|
BASE
|
|
Show details
|
|
|
|